category	number_of_genes	p_value	fdr	description
Keyword	41	1.2500000000000002e-66	8.42e-64	DNA repair
WikiPathways	34	1.55e-63	1.21e-60	DNA repair pathways, full network
Process	43	1.6200000000000003e-64	2.55e-60	DNA repair
NetworkNeighborAL	35	1.43e-62	6.520000000000001e-59	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
RCTM	37	1.56e-57	3.55e-54	DNA Repair
COMPARTMENTS	25	7.26e-50	1.67e-46	DNA repair complex
Component	24	3.7400000000000004e-49	7.66e-46	DNA repair complex
PMID	30	1.19e-51	5.21e-45	(2012) Exonuclease 1 (EXO1) gene variation and melanoma risk.
PMID	28	1.18e-49	2.5900000000000003e-43	(2019) DNA damage response and repair in perspective: Aedes aegypti, Drosophila melanogaster and Homo sapiens.
PMID	27	1.0299999999999999e-48	1.51e-42	(2017) Mechanisms of DNA damage, repair, and mutagenesis.
PMID	24	2.42e-46	2.66e-40	(2013) DNA repair mechanisms in dividing and non-dividing cells.
PMID	24	1.65e-45	1.45e-39	(2011) DNA repair deficiency in neurodegeneration.
PMID	25	4.07e-45	2.98e-39	(2014) DNA repair in cancer: emerging targets for personalized therapy.
Function	23	8.99e-43	4.43e-39	Damaged DNA binding
PMID	26	1.25e-44	7.84e-39	(2020) Focus on UV-Induced DNA Damage and Repair-Disease Relevance and Protective Strategies.
Process	27	4.98e-41	1.5600000000000002e-37	Double-strand break repair
Function	27	3.73e-40	9.2e-37	Catalytic activity, acting on DNA
Process	44	1.67e-39	4.35e-36	Nucleic acid metabolic process
PMID	23	2.7699999999999997e-41	1.5200000000000002e-35	(2019) DNA Damage Response Pathways in Dinoflagellates.
PMID	24	9.64e-40	4.7e-34	(2018) DNA Checkpoint and Repair Factors Are Nuclear Sensors for Intracellular Organelle Stresses-Inflammations and Cancers Can Have High Genomic Risks.
PMID	21	5.1e-39	2.23e-33	(2021) Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy.
PMID	22	3.02e-38	1.2e-32	(2021) DNA folds threaten genetic stability and can be leveraged for chemotherapy.
NetworkNeighborAL	22	5.33e-36	1.22e-32	DNA repair pathways, full network, and HDR through Homologous Recombination (HRR)
PMID	20	4.96e-38	1.81e-32	(2017) Coordination of DNA single strand break repair.
NetworkNeighborAL	17	6.310000000000001e-35	7.220000000000001e-32	DNA repair complex
PMID	21	2.59e-37	8.740000000000001e-32	(2021) DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment.
PMID	20	5.5700000000000004e-37	1.74e-31	(2011) Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk.
Process	18	1.08e-34	1.8900000000000001e-31	Double-strand break repair via nonhomologous end joining
PMID	21	1.03e-36	3.0200000000000004e-31	(2020) Acetylation and Deacetylation of DNA Repair Proteins in Cancers.
PMID	21	1.29e-36	3.54e-31	(2016) Balancing self-renewal against genome preservation in stem cells: How do they manage to have the cake and eat it too?
PMID	21	2e-36	5.15e-31	(2021) DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy.
PMID	21	1.56e-35	3.8e-30	(2019) Tissue specificity of DNA damage response and tumorigenesis.
PMID	19	2.47e-35	5.7099999999999994e-30	(2021) DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
PMID	20	2.64e-35	5.8000000000000005e-30	(2020) The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.
PMID	18	3.73e-35	7.78e-30	(2010) Overview of DNA Repair in Trypanosoma cruzi, Trypanosoma brucei, and Leishmania major.
PMID	19	5.84e-35	1.1600000000000001e-29	(2018) Deoxyribonucleic Acid Damage and Repair: Capitalizing on Our Understanding of the Mechanisms of Maintaining Genomic Integrity for Therapeutic Purposes.
PMID	19	1.01e-34	1.9300000000000002e-29	(2018) Mutational signatures reveal the role of RAD52 in p53-independent p21-driven genomic instability.
PMID	18	1.08e-34	1.9800000000000002e-29	(2015) New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.
PMID	19	1.33e-34	2.3300000000000002e-29	(2020) DNA Damage: From Threat to Treatment.
PMID	18	1.5199999999999998e-34	2.57e-29	(2019) PARP Inhibitors in Prostate Cancer--The Preclinical Rationale and Current Clinical Development.
PMID	18	1.5199999999999998e-34	2.57e-29	(2018) The central role of DNA damage and repair in CAG repeat diseases.
Process	17	2.1700000000000002e-32	2.62e-29	Base-excision repair
PMID	18	7.66e-34	1.2e-28	(2011) Genetic variation in DNA repair pathway genes and melanoma risk.
PMID	18	1.4100000000000001e-33	2.13e-28	(2010) Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair.
PMID	20	4.41e-33	6.45e-28	(2015) Modulation of DNA damage and repair pathways by human tumour viruses.
PMID	18	5.89e-33	8.33e-28	(2017) DNA damage related crosstalk between the nucleus and mitochondria.
PMID	18	5.89e-33	8.33e-28	(2014) DNA damage and its links to neurodegeneration.
PMID	17	7.85e-33	1.0300000000000001e-27	(2015) DNA repair and aging: the impact of the p53 family.
PMID	19	7.83e-33	1.0300000000000001e-27	(2021) Targeting the Interplay between HDACs and DNA Damage Repair for Myeloma Therapy.
PMID	18	7.74e-33	1.0300000000000001e-27	(2017) Chronic oxidative damage together with genome repair deficiency in the neurons is a double whammy for neurodegeneration: Is damage response signaling a potential therapeutic target?
PMID	17	7.85e-33	1.0300000000000001e-27	(2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair.
PMID	17	7.85e-33	1.0300000000000001e-27	(2017) The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
PMID	16	1.57e-32	1.8100000000000002e-27	(2012) Pathways for repairing and tolerating the spectrum of oxidative DNA lesions.
PMID	18	1.71e-32	1.93e-27	(2017) Drugging the Cancers Addicted to DNA Repair.
PMID	16	2.4300000000000002e-32	2.6600000000000003e-27	(2011) An update on targeted gene repair in mammalian cells: methods and mechanisms.
PMID	19	3.34e-32	3.5700000000000005e-27	(2021) DNA Damage Repair in Brain Tumor Immunotherapy.
PMID	18	3.6700000000000005e-32	3.83e-27	(2019) Treatment May Be Harmful: MechanismsPredictionPrevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma.
PMID	17	4.1300000000000004e-32	4.2100000000000006e-27	(2021) DNA End Joining: G0-ing to the Core.
WikiPathways	15	1.2200000000000001e-29	4.75e-27	Base excision repair
RCTM	20	6.48e-30	7.4e-27	DNA Double-Strand Break Repair
PMID	18	7.61e-32	7.580000000000001e-27	(2020) DNA repair fidelity in stem cell maintenance, health, and disease.
PMID	15	7.850000000000001e-32	7.650000000000001e-27	(2011) Tidying up loose ends: the role of polynucleotide kinasephosphatase in DNA strand break repair.
PMID	17	3.3e-31	3.15e-26	(2015) DNA damage and repair in plants - from models to crops.
PMID	16	3.85e-31	3.59e-26	(2016) The Response to Oxidative DNA Damage in Neurons: Mechanisms and Disease.
PMID	20	3.9400000000000004e-31	3.6e-26	(2010) The DNA damage response: making it safe to play with knives.
PMID	17	7.470000000000001e-31	6.680000000000001e-26	(2020) The Dark Side of UV-Induced DNA Lesion Repair.
PMID	17	7.470000000000001e-31	6.680000000000001e-26	(2015) DNA excision repair at telomeres.
PMID	16	7.810000000000001e-31	6.72e-26	(2019) Genetic Polymorphisms of DNA Repair Pathways in Sporadic Colorectal Carcinogenesis.
PMID	16	1.1000000000000001e-30	9.28e-26	(2019) Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting.
PMID	17	2.09e-30	1.73e-25	(2020) Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
PMID	15	2.3599999999999998e-30	1.92e-25	(2017) Base excision repair of oxidative DNA damage: from mechanism to disease.
PMID	19	2.7699999999999997e-30	2.21e-25	(2020) Autophagy Roles in Genome Maintenance.
PMID	15	3.6199999999999995e-30	2.83e-25	(2014) Comprehensive analyses of DNA repair pathways, smoking and bladder cancer risk in Los Angeles and Shanghai.
PMID	16	4.03e-30	3.1e-25	(2013) Parkinsons disease: a complex interplay of mitochondrial DNA alterations and oxidative stress.
PMID	16	5.4899999999999995e-30	4.15e-25	(2013) An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
PMID	16	1.0000000000000001e-29	7.44e-25	(2016) DNA repair targeted therapy: The past or future of cancer treatment?
PMID	14	1.2200000000000001e-29	8.92e-25	(2020) Druggable binding sites in the multicomponent assemblies that characterise DNA double-strand-break repair through non-homologous end joining.
PMID	18	1.29e-29	9.27e-25	(2022) Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
PMID	15	1.7800000000000001e-29	1.26e-24	(2009) DNA repair deficiency and neurological disease.
PMID	18	1.8400000000000002e-29	1.2799999999999999e-24	(2021) Mass spectrometry-based protein-protein interaction techniques and their applications in studies of DNA damage repair.
PMID	16	2.3600000000000002e-29	1.62e-24	(2017) Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype.
KEGG	14	4.990000000000001e-27	1.68e-24	Base excision repair
PMID	16	3.11e-29	2.1e-24	(2020) Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells.
Process	24	2.68e-27	2.63e-24	Response to radiation
PMID	15	7.53e-29	5e-24	(2021) Mechanisms of Genome Maintenance in Plants: Playing It Safe With Breaks and Bumps.
PMID	15	7.53e-29	5e-24	(2015) Recognition and repair of chemically heterogeneous structures at DNA ends.
PMID	15	7.53e-29	5e-24	(2012) Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis.
PMID	14	1.43e-28	9.09e-24	(2019) DNA Oxidation and Excision Repair Pathways.
PMID	14	1.43e-28	9.09e-24	(2014) Nonhomologous end joining: a good solution for bad ends.
PMID	14	1.43e-28	9.09e-24	(2009) Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk.
PMID	19	1.86e-28	1.13e-23	(2020) The Chromatin Response to Double-Strand DNA Breaks and Their Repair.
Function	38	9.62e-27	1.19e-23	DNA binding
PMID	15	2.03e-28	1.2199999999999999e-23	(2012) Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer.
PMID	19	2.11e-28	1.2499999999999999e-23	(2021) Unboxing the molecular modalities of mutagens in cancer.
PMID	18	2.11e-28	1.2499999999999999e-23	(2014) Emergence and evolutionary analysis of the human DDR network: implications in comparative genomics and downstream analyses.
PMID	16	3.07e-28	1.7699999999999998e-23	(2020) Evolving insights: how DNA repair pathways impact cancer evolution.
RCTM	14	2.5600000000000002e-26	1.9499999999999997e-23	Resolution of Abasic Sites (AP sites)
PMID	15	5.16e-28	2.94e-23	(2011) DNA repair: the culprit for tumor-initiating cell survival?
PMID	14	5.19e-28	2.94e-23	(2011) Oxidative genome damage and its repair in neurodegenerative diseases: function of transition metals as a double-edged sword.
PMID	14	5.19e-28	2.94e-23	(2010) Functions of disordered regions in mammalian early base excision repair proteins.
PMID	14	5.19e-28	2.94e-23	(2012) Resolution of complex ends by Nonhomologous end joining - better to be lucky than good?
Process	20	3.26e-26	3.0099999999999995e-23	DNA recombination
PMID	15	6.9499999999999995e-28	3.76e-23	(2020) Cooperation and interplay between base and nucleotide excision repair pathways: From DNA lesions to proteins.
DISEASES	13	8.240000000000001e-27	3.7899999999999995e-23	Xeroderma pigmentosum
PMID	14	1.6900000000000003e-27	9.009999999999999e-23	(2018) DNA damage repair in ovarian cancer: unlocking the heterogeneity.
Component	43	9e-26	9.209999999999999e-23	Nucleoplasm
PMID	13	1.8400000000000002e-27	9.7e-23	(2017) Systematic analysis of DNA damage induction and DNA repair pathway activation by continuous wave visible light laser micro-irradiation.
PMID	16	1.8400000000000002e-27	9.7e-23	(2015) Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.
PMID	15	2.1600000000000003e-27	1.11e-22	(2012) Base excision repair in physiology and pathology of the central nervous system.
PMID	14	2.4400000000000003e-27	1.2500000000000001e-22	(2015) DNA repair mechanisms and human cytomegalovirus (HCMV) infection.
PMID	14	2.4400000000000003e-27	1.2500000000000001e-22	(2011) Metabolism, genomics, and DNA repair in the mouse aging liver.
PMID	17	2.8e-27	1.4000000000000002e-22	(2021) Crosstalk between autophagy and DNA repair systems.
PMID	16	3.42e-27	1.68e-22	(2020) DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome.
PMID	14	4.990000000000001e-27	2.43e-22	(2020) The involvement of nucleotide excision repair proteins in the removal of oxidative DNA damage.
PMID	13	5.1e-27	2.46e-22	(2020) Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer.
NetworkNeighborAL	13	4.54e-25	2.5600000000000003e-22	Base excision repair, and DNA topological change
NetworkNeighborAL	12	4.48e-25	2.5600000000000003e-22	Nonhomologous end joining complex, and Mismatch repair complex
PMID	16	7.55e-27	3.6000000000000003e-22	(2009) Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity.
PMID	13	8.240000000000001e-27	3.8900000000000003e-22	(2011) Variation in base excision repair capacity.
PMID	14	9.83e-27	4.58e-22	(2010) Structural dynamics in DNA damage signaling and repair.
PMID	14	9.83e-27	4.58e-22	(2014) Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research.
PMID	14	9.83e-27	4.58e-22	(2014) DNA-PK: a dynamic enzyme in a versatile DSB repair pathway.
PMID	14	9.83e-27	4.58e-22	(2017) Non-bulky Lesions in Human DNA: the Ways of Formation, Repair, and Replication.
PMID	15	1.02e-26	4.58e-22	(2020) Base Excision Repair in the Immune System: Small DNA Lesions With Big Consequences.
PMID	16	1.33e-26	5.8e-22	(2021) A Link between Replicative Stress, Lamin Proteins, and Inflammation.
PMID	13	1.31e-26	5.8e-22	(2021) Searching for DNA Damage: Insights From Single Molecule Analysis.
COMPARTMENTS	44	6.49e-25	7.47e-22	Nucleus
NetworkNeighborAL	11	2.08e-24	9.52e-22	Nonhomologous end joining complex
Process	14	3.3899999999999996e-24	2.95e-21	Nucleotide-excision repair
Keyword	44	4.38e-23	9.82e-21	Nucleus
WikiPathways	14	1.05e-22	2.72e-20	Nucleotide excision repair in xeroderma pigmentosum 
Process	45	4.0699999999999996e-23	3.36e-20	Macromolecule metabolic process
RCTM	15	1.69e-22	7.72e-20	Nucleotide Excision Repair
NetworkNeighborAL	11	2.46e-22	1.02e-19	Base excision repair
RCTM	14	3.78e-22	1.44e-19	Global Genome Nucleotide Excision Repair (GG-NER)
NetworkNeighborAL	10	3.1500000000000004e-21	1.2e-18	APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway, and PNK, FHA domain
COMPARTMENTS	10	1.35e-20	1.04e-17	Nucleotide-excision repair complex
Function	39	1.34e-20	1.33e-17	Nucleic acid binding
Process	45	1.95e-20	1.53e-17	Nitrogen compound metabolic process
WikiPathways	9	7.98e-20	1.56e-17	Non-homologous end joining
Component	9	4.2e-20	1.66e-17	Nonhomologous end joining complex
Component	46	1.58e-19	3.7e-17	Nucleus
Component	9	1.45e-19	3.7e-17	Nucleotide-excision repair complex
KEGG	9	2.53e-19	4.25e-17	Non-homologous end-joining
WikiPathways	11	3.34e-19	5.22e-17	Nucleotide excision repair
KEGG	11	5.14e-19	5.76e-17	Nucleotide excision repair
Process	44	1.31e-19	9.78e-17	Cellular response to stimulus
Process	25	1.54e-19	1.09e-16	Response to abiotic stimulus
Keyword	12	1.12e-18	1.88e-16	DNA recombination
Process	45	5.26e-19	3.59e-16	Primary metabolic process
Process	9	7.01e-19	4.4e-16	Base-excision repair, gap-filling
Process	14	8.06e-19	4.86e-16	Response to UV
COMPARTMENTS	9	1.75e-18	1e-15	Nonhomologous end joining complex
Component	12	2.5e-17	5.12e-15	Site of DNA damage
Process	8	1.96e-17	1.1e-14	DNA ligation
RCTM	10	1.36e-16	4.45e-14	Nonhomologous End-Joining (NHEJ)
Process	10	1.62e-16	8.49e-14	Somatic diversification of immune receptors
DISEASES	27	6.05e-17	1.39e-13	Autosomal recessive disease
Process	15	4.95e-16	2.5e-13	Response to light stimulus
Process	11	5.16e-16	2.53e-13	DNA biosynthetic process
COMPARTMENTS	7	7.83e-16	3.6e-13	DNA ligase IV complex
Process	14	9.75e-16	4.63e-13	Nucleic acid phosphodiester bond hydrolysis
Process	12	1.1e-15	4.93e-13	Response to ionizing radiation
RCTM	9	2.49e-15	7.1e-13	Formation of Incision Complex in GG-NER
Process	9	2.05e-15	8.94e-13	Somatic diversification of immunoglobulins
RCTM	10	6.53e-15	1.54e-12	Transcription-Coupled Nucleotide Excision Repair (TC-NER)
RCTM	8	6.07e-15	1.54e-12	Resolution of AP sites via the multiple-nucleotide patch replacement pathway
COMPARTMENTS	7	4.41e-15	1.69e-12	XPC complex
Function	40	2.37e-15	1.95e-12	Heterocyclic compound binding
Function	40	3.74e-15	2.63e-12	Organic cyclic compound binding
Component	22	1.77e-14	3.29e-12	Nuclear protein-containing complex
Process	12	5.74e-14	2.31e-11	DNA replication
Process	16	5.89e-14	2.31e-11	Regulation of DNA metabolic process
NetworkNeighborAL	6	1.04e-13	3.67e-11	PNK, FHA domain, and Resolution of AP sites via the single-nucleotide replacement pathway
COMPARTMENTS	19	1.35e-13	3.89e-11	Chromosome
RCTM	8	1.92e-13	3.98e-11	Dual Incision in GG-NER
Component	24	2.48e-13	4.23e-11	Chromosome
Component	9	2.85e-13	4.48e-11	Site of double-strand break
COMPARTMENTS	24	2.48e-13	6.33e-11	Nuclear lumen
RCTM	6	3.37e-13	6.42e-11	POLB-Dependent Long Patch Base Excision Repair
WikiPathways	9	5.41e-13	7.04e-11	DNA IR-damage and cellular response via ATR
Process	19	1.84e-13	7.05e-11	Chromosome organization
Process	8	1.92e-13	7.16e-11	Somatic diversification of immune receptors via germline recombination within a single locus
Process	11	6.12e-13	2.18e-10	Cellular response to radiation
Component	10	1.86e-12	2.72e-10	Chromosome, telomeric region
COMPARTMENTS	9	1.31e-12	2.73e-10	Site of DNA damage
Function	7	4.52e-13	2.78e-10	DNA-directed DNA polymerase activity
Keyword	9	2.67e-12	3.58e-10	DNA replication
RCTM	6	2.07e-12	3.64e-10	HDR through MMEJ (alt-NHEJ)
Process	6	1.38e-12	4.82e-10	Single strand break repair
Process	8	1.61e-12	5.48e-10	Response to gamma radiation
RCTM	6	4.31e-12	7.03e-10	Early Phase of HIV Life Cycle
RCTM	8	4.89e-12	7.44e-10	Gap-filling DNA repair synthesis and ligation in TC-NER
Function	8	1.41e-12	7.7e-10	Deoxyribonuclease activity
Function	11	1.7e-12	7.7e-10	Nuclease activity
Process	9	2.45e-12	8.17e-10	Telomere maintenance
Process	7	2.76e-12	9.02e-10	Somatic recombination of immunoglobulin gene segments
Keyword	23	9.12e-12	9.26e-10	DNA-binding
Keyword	6	8.27e-12	9.26e-10	DNA-directed DNA polymerase
DISEASES	6	8.96e-13	1.37e-09	Xeroderma pigmentosum group G
RCTM	9	1.37e-11	1.95e-09	Homology Directed Repair
InterPro	7	4.52e-13	3.24e-09	BRCT domain
InterPro	7	7.44e-13	3.24e-09	BRCT domain superfamily
HPO	8	3.74e-13	3.47e-09	Papilloma
HPO	9	2.85e-13	3.47e-09	Cutaneous photosensitivity
Process	9	1.27e-11	4.08e-09	Recombinational repair
Process	5	1.37e-11	4.3e-09	DNA ligation involved in DNA repair
RCTM	6	3.25e-11	4.37e-09	PCNA-Dependent Long Patch Base Excision Repair
NetworkNeighborAL	5	1.37e-11	4.48e-09	Nonhomologous end joining complex
Process	6	1.49e-11	4.57e-09	V(D)J recombination
RCTM	5	4.29e-11	5.44e-09	APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
Keyword	5	6.96e-11	5.85e-09	Xeroderma pigmentosum
DISEASES	19	9.35e-12	8.6e-09	Syndrome
COMPARTMENTS	5	1.08e-10	1.78e-08	DNA-dependent protein kinase complex
Process	8	6.15e-11	1.82e-08	Cellular response to UV
DISEASES	5	2.51e-11	1.92e-08	Xeroderma pigmentosum variant type
Process	5	6.96e-11	2.02e-08	Nucleotide-excision repair, DNA incision
Process	5	6.96e-11	2.02e-08	Immunoglobulin V(D)J recombination
Process	10	7.88e-11	2.21e-08	Regulation of DNA repair
Process	15	9.52e-11	2.62e-08	Immune system development
SMART	6	4.13e-11	3.39e-08	Breast cancer carboxy-terminal domain
RCTM	7	3.04e-10	3.65e-08	Dual incision in TC-NER
Keyword	7	4.92e-10	3.67e-08	Nucleotidyltransferase
HPO	9	9.53e-12	3.88e-08	Telangiectasia
COMPARTMENTS	7	2.75e-10	4.21e-08	Site of double-strand break
HPO	6	1.49e-11	4.53e-08	Poikiloderma
HPO	6	1.49e-11	4.53e-08	Entropion
Process	11	1.73e-10	4.68e-08	Regulation of response to DNA damage stimulus
NetworkNeighborAL	5	1.62e-10	4.94e-08	Nucleotide-excision repair complex, and XPG/Rad2 endonuclease, eukaryotes
Function	34	1.52e-10	6.25e-08	Catalytic activity
Process	6	2.51e-10	6.45e-08	Response to X-ray
HPO	6	3.25e-11	6.61e-08	Conjunctival telangiectasia
HPO	9	4.23e-11	7.37e-08	Dry skin
HPO	8	5.2e-11	7.93e-08	Dermal atrophy
Process	5	3.32e-10	8.41e-08	UV protection
HPO	5	6.96e-11	8.79e-08	Flat nasal alae
DISEASES	5	1.62e-10	9.3e-08	Cockayne syndrome
HPO	7	1.03e-10	1.14e-07	Telangiectasia of the skin
Component	33	9.53e-10	1.22e-07	Protein-containing complex
COMPARTMENTS	13	9.8e-10	1.41e-07	Nucleolus
Function	6	4.12e-10	1.56e-07	Endodeoxyribonuclease activity
Function	5	4.59e-10	1.62e-07	DNA N-glycosylase activity
NetworkNeighborAL	5	6.22e-10	1.78e-07	Mixed, incl. Xeroderma pigmentosum variant type, and Rad18-like CCHC zinc finger
Function	8	5.65e-10	1.86e-07	Endonuclease activity
Function	5	6.22e-10	1.92e-07	Mismatched DNA binding
Process	11	8.24e-10	2.02e-07	Response to oxidative stress
HPO	7	2.01e-10	2.05e-07	Melanoma
RCTM	4	1.79e-09	2.05e-07	Resolution of AP sites via the single-nucleotide replacement pathway
HPO	7	2.01e-10	2.05e-07	Keratitis
Component	4	1.79e-09	2.16e-07	DNA-dependent protein kinase-DNA ligase 4 complex
Component	14	1.99e-09	2.27e-07	Intracellular protein-containing complex
COMPARTMENTS	4	1.79e-09	2.43e-07	DNA-dependent protein kinase-DNA ligase 4 complex
Function	7	9.15e-10	2.65e-07	Exonuclease activity
HPO	9	3.57e-10	2.9e-07	Neoplasm of the skin
RCTM	8	2.7e-09	2.93e-07	HIV Life Cycle
COMPARTMENTS	32	2.39e-09	3.06e-07	Protein-containing complex
DISEASES	28	6.31e-10	3.22e-07	Genetic disease
Process	15	1.4e-09	3.39e-07	Nucleobase-containing compound biosynthetic process
Process	8	1.44e-09	3.41e-07	DNA-templated DNA replication
HPO	5	4.59e-10	3.5e-07	Defective DNA repair after ultraviolet radiation damage
Keyword	4	5.36e-09	3.6e-07	Cockayne syndrome
Keyword	12	6.97e-09	4.26e-07	Magnesium
HPO	5	6.22e-10	4.31e-07	Ankyloblepharon
HPO	8	6.01e-10	4.31e-07	Abnormal conjunctiva morphology
HPO	6	7.53e-10	4.83e-07	Freckling
HPO	10	8.64e-10	5.27e-07	Neoplasm by histology
Process	8	2.7e-09	6.31e-07	Negative regulation of DNA metabolic process
RCTM	5	7.48e-09	7.77e-07	Gap-filling DNA repair synthesis and ligation in GG-NER
Function	46	2.88e-09	7.89e-07	Binding
HPO	14	1.41e-09	8.15e-07	Neoplasm
DISEASES	4	1.79e-09	8.23e-07	Xeroderma pigmentosum group C
COMPARTMENTS	25	7.88e-09	8.24e-07	Intracellular non-membrane-bounded organelle
RCTM	4	8.4e-09	8.34e-07	2-LTR circle formation
HPO	6	1.9e-09	1.01e-06	Neoplasm of the eye
HPO	16	2.41e-09	1.22e-06	Abnormal reproductive system morphology
Function	5	6.25e-09	1.62e-06	Exodeoxyribonuclease activity, producing 5-phosphomonoesters
RCTM	4	1.81e-08	1.73e-06	Displacement of DNA glycosylase by APEX1
HPO	6	3.78e-09	1.78e-06	Ectropion
Keyword	4	4.6e-08	2.57e-06	DNA synthesis
Process	7	1.2e-08	2.68e-06	Double-strand break repair via homologous recombination
COMPARTMENTS	7	2.98e-08	2.74e-06	Serine/threonine protein kinase complex
Process	5	1.69e-08	3.73e-06	Mismatch repair
Function	7	1.68e-08	3.76e-06	Single-stranded DNA binding
HPO	13	9.11e-09	3.97e-06	Neoplasm by anatomical site
RCTM	5	4.94e-08	4.34e-06	DNA Damage Recognition in GG-NER
HPO	11	1.05e-08	4.44e-06	Abnormal cellular physiology
Process	4	2.54e-08	5.45e-06	Transcription-coupled nucleotide-excision repair
WikiPathways	7	5.55e-08	6.19e-06	Male infertility
RCTM	4	7.7e-08	6.28e-06	Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
RCTM	4	9.74e-08	7.67e-06	Processive synthesis on the lagging strand
HPO	5	1.96e-08	7.71e-06	Craniofacial hyperostosis
Process	9	3.71e-08	7.86e-06	Positive regulation of DNA metabolic process
HPO	14	2.24e-08	8.54e-06	Abnormality of the male genitalia
Keyword	5	1.75e-07	9.04e-06	Exonuclease
Process	4	4.6e-08	9.61e-06	Base-excision repair, AP site formation
Process	4	4.6e-08	9.61e-06	Somatic hypermutation of immunoglobulin genes
Function	4	6e-08	1.23e-05	DNA-(apurinic or apyrimidinic site) endonuclease activity
Keyword	4	2.65e-07	1.27e-05	SCID
COMPARTMENTS	4	1.5e-07	1.28e-05	Enzyme activator complex
HPO	5	3.86e-08	1.39e-05	Pterygium
HPO	6	4.04e-08	1.4e-05	Opacification of the corneal stroma
HPO	10	4.01e-08	1.4e-05	Peripheral neuropathy
HPO	6	4.34e-08	1.43e-05	Conjunctivitis
HPO	8	4.83e-08	1.55e-05	Photophobia
RCTM	4	2.21e-07	1.63e-05	Processive synthesis on the C-strand of the telomere
Function	11	8.68e-08	1.71e-05	Chromatin binding
Function	20	8.7e-08	1.71e-05	Hydrolase activity
Keyword	16	3.87e-07	1.73e-05	Hydrolase
COMPARTMENTS	14	2.2e-07	1.81e-05	Nucleoplasm
Component	3	2.36e-07	2.1e-05	DNA ligase IV complex
Component	3	2.36e-07	2.1e-05	XPC complex
HPO	4	7.7e-08	2.24e-05	Bird-like facies
Component	6	2.79e-07	2.29e-05	Serine/threonine protein kinase complex
HPO	10	8.56e-08	2.43e-05	Hypoplastic male external genitalia
HPO	5	8.72e-08	2.43e-05	Blepharitis
HPO	8	8.98e-08	2.44e-05	Fever
Component	13	3.16e-07	2.49e-05	Nucleolus
Keyword	6	6.26e-07	2.63e-05	Nuclease
WikiPathways	5	2.72e-07	2.66e-05	DNA IR-double strand breaks and cellular response via ATM
Keyword	19	6.76e-07	2.67e-05	Ubl conjugation
HPO	16	1.11e-07	2.88e-05	Abnormality of the nose
HPO	9	1.2e-07	3.02e-05	Abnormality of temperature regulation
HPO	5	1.19e-07	3.02e-05	Basal cell carcinoma
Component	3	4.11e-07	3.12e-05	DNA-dependent protein kinase complex
Process	6	1.63e-07	3.28e-05	DNA modification
Keyword	16	8.99e-07	3.36e-05	Isopeptide bond
COMPARTMENTS	7	4.46e-07	3.54e-05	protein-DNA complex
HPO	13	1.51e-07	3.6e-05	Abnormality of male external genitalia
HPO	6	1.54e-07	3.62e-05	Erythema
KEGG	4	4.35e-07	3.65e-05	Mismatch repair
HPO	7	1.58e-07	3.65e-05	Decreased circulating antibody level
HPO	4	1.83e-07	4.13e-05	Squamous cell carcinoma of the skin
Function	3	2.36e-07	4.3e-05	DNA ligase (ATP) activity
Function	6	2.65e-07	4.51e-05	Protein N-terminus binding
HPO	15	2.06e-07	4.56e-05	Abnormality of skull size
Function	6	2.79e-07	4.59e-05	ATP-dependent activity, acting on DNA
Function	31	3.23e-07	4.98e-05	Ion binding
Function	7	3.65e-07	5.45e-05	Protein C-terminus binding
RCTM	16	8e-07	5.53e-05	Disease
HPO	8	2.92e-07	6.15e-05	Abnormality of the vasculature of the eye
COMPARTMENTS	8	8.4e-07	6.44e-05	Transferase complex, transferring phosphorus-containing groups
Keyword	23	1.82e-06	6.44e-05	Metal-binding
RCTM	12	9.69e-07	6.51e-05	Infectious disease
HPO	5	3.21e-07	6.65e-05	Squamous cell carcinoma
HPO	9	3.24e-07	6.65e-05	Thickened skin
Keyword	6	2.06e-06	6.91e-05	Lyase
Process	15	3.64e-07	7.23e-05	Macromolecule biosynthetic process
HPO	4	3.71e-07	7.3e-05	Colorectal polyposis
HPO	7	3.65e-07	7.3e-05	Immunodeficiency
HPO	7	3.77e-07	7.31e-05	Alopecia
Function	5	5.13e-07	7.43e-05	DNA helicase activity
Component	7	1.05e-06	7.44e-05	protein-DNA complex
HPO	10	4.01e-07	7.64e-05	Puberty and gonadal disorders
HPO	5	4.08e-07	7.66e-05	Melanocytic nevus
Function	16	5.78e-07	8.14e-05	Double-stranded DNA binding
Function	3	6.57e-07	9e-05	5-deoxyribose-5-phosphate lyase activity
RCTM	4	1.44e-06	9.38e-05	Termination of translesion DNA synthesis
HPO	5	5.13e-07	9.48e-05	Intellectual disability, progressive
DISEASES	3	2.36e-07	9.84e-05	Severe combined immunodeficiency with sensitivity to ionizing radiation
DISEASES	3	2.36e-07	9.84e-05	DNA ligase IV deficiency
TISSUES	10	4.28e-08	0.0001	Lymphocytic leukemia cell
Keyword	6	3.21e-06	0.0001	Dwarfism
HPO	20	6.03e-07	0.00011	Abnormality of the face
HPO	13	7.07e-07	0.00012	Abnormality of the endocrine system
Process	4	5.87e-07	0.00012	Translesion synthesis
HPO	13	7.85e-07	0.00013	Microcephaly
HPO	9	7.69e-07	0.00013	Abnormality of skin pigmentation
Process	3	6.57e-07	0.00013	Error-free translesion synthesis
Process	6	6.84e-07	0.00013	Positive regulation of DNA repair
Process	3	6.57e-07	0.00013	Double-strand break repair via alternative nonhomologous end joining
COMPARTMENTS	3	1.93e-06	0.00014	PCNA complex
HPO	18	8.89e-07	0.00014	Abnormality of the genitourinary system
HPO	13	8.52e-07	0.00014	Decreased head circumference
Process	6	7.78e-07	0.00014	Regulation of DNA recombination
Keyword	5	4.67e-06	0.00014	ADP-ribosylation
KEGG	4	2.22e-06	0.00015	DNA replication
DISEASES	3	4.11e-07	0.00015	Spinocerebellar ataxia type 1 with axonal neuropathy
Process	6	8.82e-07	0.00016	Regulation of double-strand break repair
HPO	14	9.94e-07	0.00016	Aplasia/Hypoplasia of the cerebrum
RCTM	6	2.81e-06	0.00017	SUMO E3 ligases SUMOylate target proteins
Process	3	9.84e-07	0.00018	Double-strand break repair via classical nonhomologous end joining
Process	4	1e-06	0.00018	Cellular response to gamma radiation
NetworkNeighborAL	3	6.57e-07	0.00018	Xeroderma pigmentosum group A, and XFE progeroid syndrome
Process	3	9.84e-07	0.00018	Mitochondrial DNA repair
HPO	15	1.22e-06	0.00019	Aplasia/Hypoplasia involving the central nervous system
Component	9	2.89e-06	0.00019	Transcription regulator complex
Process	5	1.16e-06	0.0002	Cellular response to ionizing radiation
HPO	8	1.33e-06	0.0002	Hypogonadism
HPO	10	1.45e-06	0.00022	Cryptorchidism
HPO	14	1.51e-06	0.00022	Abnormality of immune system physiology
HPO	5	1.57e-06	0.00023	Thin skin
HPO	9	1.59e-06	0.00023	Dysarthria
HPO	11	1.62e-06	0.00023	Abnormal cerebellum morphology
HPO	11	1.72e-06	0.00024	Abnormal testis morphology
WikiPathways	5	2.72e-06	0.00024	p53 transcriptional gene network
Function	3	1.93e-06	0.00024	Oxidized DNA binding
Component	27	3.86e-06	0.00025	Intracellular non-membrane-bounded organelle
HPO	12	1.95e-06	0.00026	Increased inflammatory response
HPO	11	2.26e-06	0.00029	Abnormal external nose morphology
HPO	11	2.4e-06	0.00031	Generalized abnormality of skin
HPO	3	2.57e-06	0.00032	Numerous pigmented freckles
Process	3	1.93e-06	0.00033	Pyrimidine dimer repair
HPO	9	2.84e-06	0.00035	Reduced tendon reflexes
Process	46	2.14e-06	0.00036	Cellular process
InterPro	4	1.5e-07	0.00036	DNA/RNA polymerase superfamily
RCTM	3	6.49e-06	0.00036	IRF3-mediated induction of type I IFN
Component	7	6.39e-06	0.00038	Transferase complex, transferring phosphorus-containing groups
TISSUES	4	3.15e-07	0.00038	Skin fibroblast cell line
HPO	15	3.18e-06	0.00039	Abnormality of the urinary system
HPO	3	3.33e-06	0.0004	Abnormality of amino acid metabolism
DISEASES	5	1.23e-06	0.0004	Combined immunodeficiency
HPO	10	3.41e-06	0.00041	Abnormal hair quantity
HPO	11	3.49e-06	0.00041	Ataxia
RCTM	3	7.86e-06	0.00042	Removal of the Flap Intermediate
InterPro	3	2.36e-07	0.00042	PNK, FHA domain
InterPro	3	4.11e-07	0.00042	DNA polymerase, thumb domain superfamily
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent, N-terminal domain superfamily
InterPro	3	4.11e-07	0.00042	DNA polymerase beta, thumb domain
InterPro	3	4.11e-07	0.00042	DNA polymerase beta, palm domain
InterPro	3	6.57e-07	0.00042	DNA polymerase lambda lyase domain superfamily
InterPro	3	4.11e-07	0.00042	DNA polymerase family X
InterPro	3	4.11e-07	0.00042	DNA polymerase family X, binding site
InterPro	3	4.11e-07	0.00042	DNA polymerase lambda, fingers domain
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent, conserved site
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent, C-terminal
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent, central
Process	22	2.57e-06	0.00042	Organelle organization
RCTM	3	7.86e-06	0.00042	Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent
InterPro	3	4.11e-07	0.00042	DNA polymerase beta-like, N-terminal domain
InterPro	3	2.36e-07	0.00042	DNA ligase, ATP-dependent, N-terminal
InterPro	3	4.11e-07	0.00042	DNA-directed DNA polymerase X
HPO	13	3.77e-06	0.00043	Abnormal nasal morphology
HPO	18	3.71e-06	0.00043	Morphological central nervous system abnormality
HPO	6	3.65e-06	0.00043	Hypopigmentation of the skin
RCTM	4	9.3e-06	0.00046	Formation of TC-NER Pre-Incision Complex
HPO	7	4.2e-06	0.00048	Delayed skeletal maturation
HPO	19	4.26e-06	0.00048	Abnormality of the skeletal system
Process	3	3.33e-06	0.00053	Positive regulation of ligase activity
Function	13	4.33e-06	0.00053	Protein-containing complex binding
HPO	17	4.97e-06	0.00055	Abnormal axial skeleton morphology
HPO	16	4.88e-06	0.00055	Abnormal skull morphology
HPO	5	4.89e-06	0.00055	Hypopigmented skin patches
DISEASES	3	1.93e-06	0.00059	Trichothiodystrophy
DISEASES	4	2e-06	0.00059	Severe combined immunodeficiency
HPO	4	5.49e-06	0.0006	Demyelinating peripheral neuropathy
RCTM	3	1.31e-05	0.00062	Removal of the Flap Intermediate from the C-strand
Pfam	3	2.36e-07	0.00064	ATP dependent DNA ligase C terminal region        
Pfam	3	2.36e-07	0.00064	DNA ligase N terminus
HPO	7	6.12e-06	0.00066	Hyperpigmentation of the skin
TISSUES	8	8.4e-07	0.00068	Cervical carcinoma cell
Process	10	4.55e-06	0.00071	Hematopoietic or lymphoid organ development
HPO	17	6.65e-06	0.00071	Abnormality of brain morphology
HPO	6	6.7e-06	0.00071	Hypermelanotic macule
HPO	5	6.96e-06	0.00073	Abnormal rectum morphology
HPO	17	7.14e-06	0.00074	Abnormality of the integument
HPO	10	7.27e-06	0.00075	Atrophy/Degeneration affecting the central nervous system
HPO	18	7.81e-06	0.00079	Abnormal nervous system morphology
HPO	15	7.93e-06	0.0008	Abnormal cerebral morphology
Keyword	33	2.81e-05	0.00082	Phosphoprotein
Component	4	1.48e-05	0.00086	Replication fork
Process	5	5.85e-06	0.00087	Hematopoietic progenitor cell differentiation
HPO	4	8.66e-06	0.00087	Erythroderma
Process	6	5.79e-06	0.00087	B cell activation
DISEASES	4	3.27e-06	0.00088	Autosomal recessive cerebellar ataxia
HPO	18	9.06e-06	0.0009	Abnormal skeletal morphology
HPO	11	9.07e-06	0.0009	Abnormality of coordination
Keyword	8	3.45e-05	0.00096	Host-virus interaction
DISEASES	30	3.81e-06	0.00097	Disease
Keyword	4	3.76e-05	0.001	Endonuclease
HPO	19	1.04e-05	0.001	Abnormality of the eye
HPO	12	1.12e-05	0.0011	Abnormality of skin adnexa morphology
HPO	5	1.22e-05	0.0011	Decreased testicular size
HPO	5	1.22e-05	0.0011	Arthralgia
HPO	7	1.13e-05	0.0011	Abnormality of skeletal maturation
HPO	5	1.26e-05	0.0012	Aminoaciduria
Process	14	8.42e-06	0.0012	Negative regulation of nucleobase-containing compound metabolic process
HPO	4	1.39e-05	0.0013	Decreased circulating IgG level
HPO	3	1.53e-05	0.0014	Severe combined immunodeficiency
HPO	17	1.58e-05	0.0014	Abnormal eye physiology
HPO	3	1.53e-05	0.0014	Cutaneous melanoma
HPO	3	1.53e-05	0.0014	Adenomatous colonic polyposis
Process	3	9.42e-06	0.0014	DNA strand elongation involved in DNA replication
Process	3	9.42e-06	0.0014	Response to UV-C
HPO	7	1.62e-05	0.0014	Cerebellar atrophy
HPO	10	1.7e-05	0.0014	Abnormality of the dentition
HPO	12	1.74e-05	0.0015	Abnormal ocular adnexa morphology
HPO	16	1.83e-05	0.0015	Abnormality of metabolism/homeostasis
KEGG	4	2.63e-05	0.0015	Platinum drug resistance
RCTM	2	3.18e-05	0.0015	Abasic sugar-phosphate removal via the single-nucleotide replacement pathway
RCTM	4	3.41e-05	0.0016	SUMOylation of DNA damage response and repair proteins
COMPARTMENTS	14	2.34e-05	0.0016	Catalytic complex
HPO	9	1.97e-05	0.0016	Abnormality of reproductive system physiology
HPO	16	1.98e-05	0.0016	Growth abnormality
HPO	8	1.95e-05	0.0016	Anemia
HPO	3	2.03e-05	0.0016	Panhypogammaglobulinemia
Process	13	1.08e-05	0.0016	Regulation of response to stress
HPO	8	2.06e-05	0.0017	Abnormal myelination
HPO	11	2.2e-05	0.0017	Abnormal hair morphology
HPO	4	2.11e-05	0.0017	Neoplasm of the colon
Component	2	3.18e-05	0.0018	Ku70:Ku80 complex
Component	2	3.18e-05	0.0018	Shu complex
Function	3	1.53e-05	0.0018	5-3 exonuclease activity
HPO	9	2.38e-05	0.0019	Brain atrophy
COMPARTMENTS	4	2.78e-05	0.0019	Chromosome, telomeric region
HPO	13	2.59e-05	0.002	Abnormality of eye movement
HPO	4	2.63e-05	0.002	Arteriosclerosis
HPO	5	2.61e-05	0.002	Aplasia/Hypoplasia of the testes
Process	16	1.39e-05	0.002	Immune system process
COMPARTMENTS	2	3.18e-05	0.0021	Ku70:Ku80 complex
Function	23	2.04e-05	0.0023	Metal ion binding
WikiPathways	3	2.96e-05	0.0023	DNA mismatch repair
Function	3	2.03e-05	0.0023	DNA polymerase binding
HPO	6	3.23e-05	0.0025	Fatigue
HPO	15	3.4e-05	0.0025	Abnormality of limbs
HPO	9	3.3e-05	0.0025	Abnormal cerebral cortex morphology
HPO	13	3.28e-05	0.0025	Growth delay
HPO	3	3.33e-05	0.0025	Keratoconjunctivitis sicca
Process	9	1.88e-05	0.0026	Hemopoiesis
TISSUES	12	4.61e-06	0.0028	Leukemia cell
Process	3	2.03e-05	0.0028	Hematopoietic stem cell differentiation
Function	3	2.63e-05	0.0029	DNA damage sensor activity
HPO	20	4.18e-05	0.003	Abnormality of the nervous system
HPO	19	4.27e-05	0.0031	Abnormality of the musculoskeletal system
DISEASES	8	1.29e-05	0.0031	Primary immunodeficiency disease
Keyword	3	0.00012	0.0031	4Fe-4S
HPO	3	4.6e-05	0.0033	Stomach cancer
Function	2	3.18e-05	0.0033	Purine-specific mismatch base pair DNA N-glycosylase activity
Function	2	3.18e-05	0.0033	DNA end binding
Function	2	3.18e-05	0.0033	Polynucleotide 3-phosphatase activity
Function	2	3.18e-05	0.0033	8-oxo-7,8-dihydroguanine DNA N-glycosylase activity
Function	8	3.58e-05	0.0034	ATP-dependent activity
HPO	9	4.74e-05	0.0034	Localized skin lesion
HPO	15	4.75e-05	0.0034	Abnormal eye morphology
HPO	12	4.91e-05	0.0035	Neurological speech impairment
HPO	11	5.2e-05	0.0036	Abnormal fundus morphology
HPO	6	5.35e-05	0.0037	Pes cavus
HPO	3	5.6e-05	0.0038	Adipose tissue loss
HPO	11	5.58e-05	0.0038	Short stature
HPO	9	5.53e-05	0.0038	Sensorineural hearing impairment
Function	4	4.14e-05	0.0039	Carbon-oxygen lyase activity
HPO	10	5.76e-05	0.0039	Hypertonia
HPO	9	6.06e-05	0.004	Abnormal calvaria morphology
HPO	11	5.99e-05	0.004	Abnormality of vision
Process	6	2.9e-05	0.004	Regulation of chromosome organization
TISSUES	8	8.35e-06	0.0041	Bone marrow cancer cell
HPO	9	6.24e-05	0.0041	Abnormal cerebral ventricle morphology
Process	2	3.18e-05	0.0043	Positive regulation of single strand break repair
Process	2	3.18e-05	0.0043	Nucleotide-excision repair, DNA duplex unwinding
Function	10	4.86e-05	0.0044	Transferase activity, transferring phosphorus-containing groups
Process	3	3.33e-05	0.0044	Nuclear DNA replication
HPO	3	6.73e-05	0.0044	B lymphocytopenia
HPO	14	6.97e-05	0.0045	Abnormality of the skin
Function	2	5.29e-05	0.0047	DNA-dependent protein kinase activity
Function	2	5.29e-05	0.0047	DNA insertion or deletion binding
Function	2	5.29e-05	0.0047	NAD DNA ADP-ribosyltransferase activity
HPO	8	7.42e-05	0.0047	Cerebral atrophy
HPO	13	7.31e-05	0.0047	Abnormality of skin morphology
HPO	6	7.33e-05	0.0047	Sparse hair
RCTM	2	0.00011	0.0049	Diseases of Base Excision Repair
COMPARTMENTS	2	7.92e-05	0.0049	Shu complex
HPO	16	7.75e-05	0.0049	Abnormality of the cardiovascular system
Process	4	3.95e-05	0.0051	Stem cell proliferation
HPO	6	8.31e-05	0.0053	Developmental regression
HPO	4	8.58e-05	0.0054	Choreoathetosis
HPO	13	8.53e-05	0.0054	Abnormality of the vasculature
HPO	8	8.88e-05	0.0055	Atrophy/Degeneration affecting the cerebrum
DISEASES	9	2.38e-05	0.0055	Immune system disease
HPO	5	9.02e-05	0.0056	Aplasia/Hypoplasia of the nails
HPO	3	9.43e-05	0.0058	Colon cancer
HPO	13	9.39e-05	0.0058	Abnormal central motor function
HPO	9	9.81e-05	0.006	Functional abnormality of the inner ear
Keyword	5	0.00024	0.006	Deafness
HPO	4	0.0001	0.0061	Sparse scalp hair
HPO	12	0.0001	0.0061	Abnormality of limb bone morphology
HPO	7	0.0001	0.0061	Abnormality of central nervous system electrophysiology
HPO	7	0.00011	0.0064	Intrauterine growth retardation
Process	4	4.98e-05	0.0064	Negative regulation of response to DNA damage stimulus
Function	2	7.92e-05	0.0065	Double-stranded DNA exodeoxyribonuclease activity
Function	2	7.92e-05	0.0065	Uracil DNA N-glycosylase activity
Keyword	11	0.00027	0.0065	ATP-binding
Function	15	7.79e-05	0.0065	Nucleotide binding
HPO	3	0.00011	0.0065	High pitched voice
HPO	4	0.00011	0.0066	Skin rash
Process	2	5.29e-05	0.0067	Small-subunit processome assembly
HPO	8	0.00011	0.0067	Cataract
COMPARTMENTS	2	0.00011	0.0067	Cyclin-dependent protein kinase activating kinase holoenzyme complex
Process	2	5.29e-05	0.0067	DNA ADP-ribosylation
Process	2	5.29e-05	0.0067	Peptidyl-serine ADP-ribosylation
Process	2	5.29e-05	0.0067	Negative regulation of protein ADP-ribosylation
Process	15	5.43e-05	0.0067	Gene expression
Process	7	5.6e-05	0.0068	Response to xenobiotic stimulus
HPO	7	0.00012	0.0069	Abnormal urine metabolite level
HPO	11	0.00012	0.0069	Abnormality of body height
HPO	3	0.00012	0.0069	Abnormal astrocyte morphology
DISEASES	2	3.18e-05	0.007	Xeroderma pigmentosum group B
HPO	4	0.00012	0.0072	Hypotelorism
HPO	11	0.00013	0.0073	Abnormal digit morphology
HPO	10	0.00013	0.0073	Abnormal reflex
RCTM	3	0.00018	0.0077	Base-Excision Repair, AP Site Formation
HPO	11	0.00014	0.0078	Abnormal homeostasis
Process	16	6.5e-05	0.0078	Negative regulation of nitrogen compound metabolic process
HPO	12	0.00014	0.008	Abnormality of body weight
HPO	24	0.00014	0.008	Phenotypic abnormality
Function	3	0.00011	0.008	Telomeric DNA binding
HPO	2	0.00015	0.0082	Increased cellular sensitivity to UV light
HPO	3	0.00015	0.0082	Urticaria
Keyword	4	0.00036	0.0083	Helicase
HPO	11	0.00015	0.0083	Hearing impairment
HPO	15	0.00015	0.0084	Abnormality of higher mental function
HPO	3	0.00016	0.0085	Decreased circulating IgA level
HPO	3	0.00016	0.0085	Abnormality of the thymus
HPO	8	0.00016	0.0085	Abnormal cornea morphology
HPO	6	0.00016	0.0085	Hydrocephalus
HPO	4	0.00016	0.0087	Lymphopenia
HPO	5	0.00016	0.0087	Micropenis
HPO	3	0.00017	0.0089	Confusion
Function	5	0.00013	0.0091	Lyase activity
HPO	6	0.00018	0.0093	Hyporeflexia
Process	2	7.92e-05	0.0094	pro-B cell differentiation
Process	2	7.92e-05	0.0094	Lagging strand elongation
Process	2	7.92e-05	0.0094	Depurination
HPO	6	0.00018	0.0096	Epidermal thickening
HPO	2	0.00019	0.0099	Impaired social reciprocity
HPO	2	0.00019	0.0099	Tiger tail banding
HPO	2	0.00019	0.0099	Congenital exfoliative erythroderma
HPO	2	0.00019	0.0099	Hypoplasia of mandible relative to maxilla
HPO	7	0.00019	0.01	Abnormal cellular immune system morphology
HPO	7	0.00019	0.01	Abnormal leukocyte morphology
HPO	11	0.0002	0.0101	Abnormal musculoskeletal physiology
HPO	5	0.0002	0.0101	Abnormality of extrapyramidal motor function
TISSUES	2	3.18e-05	0.0102	CHO-EM9 cell
TISSUES	8	2.94e-05	0.0102	Bone marrow
HPO	14	0.0002	0.0102	Abnormal muscle physiology
TISSUES	2	3.18e-05	0.0102	46BR.1G1 cell
HPO	9	0.00021	0.0103	Spasticity
RCTM	3	0.00026	0.0104	Diseases of DNA repair
HPO	4	0.00021	0.0104	Cerebral calcification
Function	2	0.00015	0.0104	RNA-DNA hybrid ribonuclease activity
HPO	4	0.00021	0.0104	Abnormal temporal lobe morphology
HPO	9	0.00022	0.0106	Strabismus
HPO	6	0.00022	0.0106	Abnormal leukocyte count
HPO	13	0.00022	0.0107	Behavioral abnormality
HPO	3	0.00023	0.011	Short chin
DISEASES	2	5.29e-05	0.011	Xeroderma pigmentosum group D
HPO	15	0.00023	0.011	Abnormality of the musculature
DISEASES	2	5.29e-05	0.011	Xeroderma pigmentosum group A
HPO	7	0.00023	0.011	Abnormal morphology of the nasal alae
COMPARTMENTS	2	0.00019	0.0112	ERCC4-ERCC1 complex
Keyword	6	0.00051	0.0112	Chromosome
HPO	5	0.00024	0.0113	Abnormal granulocyte count
InterPro	2	3.18e-05	0.0114	Zinc finger, PARP-type
InterPro	2	3.18e-05	0.0114	DNA polymerase family X, beta-like
InterPro	2	3.18e-05	0.0114	Ku70/Ku80 C-terminal arm
InterPro	3	3.72e-05	0.0114	Nucleotidyltransferase superfamily
COMPARTMENTS	9	0.0002	0.0114	Transferase complex
InterPro	2	3.18e-05	0.0114	Ku70/Ku80, N-terminal alpha/beta
InterPro	2	3.18e-05	0.0114	Ku70/Ku80 beta-barrel domain
InterPro	2	3.18e-05	0.0114	Zinc finger, PARP-type superfamily
InterPro	2	3.18e-05	0.0114	XRCC4-like, N-terminal domain superfamily
HPO	3	0.00024	0.0115	Recurrent viral infections
HPO	5	0.00025	0.0116	Hyperkeratosis
HPO	11	0.00024	0.0116	Abnormal ear physiology
Function	3	0.00017	0.0116	4 iron, 4 sulfur cluster binding
HPO	4	0.00025	0.0117	Neoplasm of the central nervous system
HPO	12	0.00025	0.0117	Seizure
HPO	5	0.00025	0.0117	Microphthalmia
HPO	4	0.00026	0.012	Carious teeth
Function	6	0.00018	0.012	RNA polymerase II-specific DNA-binding transcription factor binding
HPO	4	0.00026	0.012	Athetosis
HPO	9	0.00028	0.0126	Abnormality of the urinary system physiology
HPO	9	0.00028	0.0128	Nystagmus
Function	2	0.00019	0.0128	Mismatch repair complex binding
Function	2	0.00019	0.0128	Oxidized purine DNA binding
Process	2	0.00011	0.0129	Positive regulation of DNA ligation
Process	2	0.00011	0.0129	T cell receptor V(D)J recombination
Process	4	0.00011	0.0129	Regulation of telomere maintenance
Process	2	0.00011	0.0129	Nucleotide-excision repair, DNA gap filling
SMART	2	5.29e-05	0.013	Proposed nucleic acid binding domain
HPO	2	0.00029	0.013	Split nail
HPO	2	0.00029	0.013	Low-set nipples
HPO	2	0.00029	0.013	Severe B lymphocytopenia
HPO	2	0.00029	0.013	Bronchospasm
SMART	2	3.18e-05	0.013	Ku70 and Ku80 are 70kDa and 80kDa subunits of the Lupus Ku autoantigen
SMART	2	5.29e-05	0.013	Endonuclease III
SMART	2	3.18e-05	0.013	Poly(ADP-ribose) polymerase and DNA-Ligase Zn-finger region
Keyword	12	0.00062	0.013	Nucleotide-binding
HPO	9	0.0003	0.0132	Abnormal involuntary eye movements
Function	14	0.0002	0.0132	Enzyme binding
HPO	6	0.0003	0.0133	Abnormal internal genitalia
HPO	13	0.00031	0.0134	Abnormal oral cavity morphology
HPO	13	0.00031	0.0135	Cognitive impairment
HPO	9	0.00031	0.0136	Failure to thrive
HPO	4	0.00031	0.0136	Prematurely aged appearance
InterPro	2	5.29e-05	0.0136	Helix-hairpin-helix, base-excision DNA repair, C-terminal
InterPro	2	5.29e-05	0.0136	WGR domain
InterPro	2	5.29e-05	0.0136	HhH-GPD domain
HPO	4	0.00031	0.0136	Abnormal thyroid morphology
InterPro	2	5.29e-05	0.0136	WGR domain superfamily
Process	21	0.00013	0.0141	Regulation of nucleobase-containing compound metabolic process
Process	4	0.00013	0.0141	Positive regulation of chromosome organization
Process	6	0.00013	0.0141	Regulation of mitotic cell cycle phase transition
Process	15	0.00013	0.0141	Negative regulation of cellular metabolic process
HPO	3	0.00033	0.0144	Neuroepithelial neoplasm
HPO	2	0.00035	0.0147	Abnormal bronchus physiology
HPO	3	0.00035	0.0149	Cachexia
SMART	2	0.00015	0.0151	Helix-hairpin-helix DNA-binding motif class 1
SMART	2	0.00011	0.0151	Helix-hairpin-helix class 2 (Pol1 family) motifs
SMART	2	0.00011	0.0151	Xeroderma pigmentosum G I-region
SMART	2	0.00011	0.0151	Xeroderma pigmentosum G N-region
DISEASES	2	7.92e-05	0.0152	Familial adenomatous polyposis 2
DISEASES	2	7.92e-05	0.0152	Xeroderma pigmentosum group F
Function	2	0.00024	0.0153	Bubble DNA binding
Function	2	0.00024	0.0153	5-3 exodeoxyribonuclease activity
HPO	5	0.00036	0.0153	Cerebral cortical atrophy
Function	2	0.00024	0.0153	Single-stranded DNA endodeoxyribonuclease activity
Keyword	3	0.00077	0.0156	Multifunctional enzyme
Process	2	0.00015	0.0159	B cell lineage commitment
Process	2	0.00015	0.0159	Cellular response to UV-C
HPO	3	0.00039	0.0162	Malignant neoplasm of the central nervous system
RCTM	3	0.00041	0.0163	HDACs deacetylate histones
HPO	4	0.0004	0.0166	Abnormality of corneal size
RCTM	3	0.00043	0.0168	Regulation of PTEN gene transcription
Function	3	0.00027	0.0169	3-5 exonuclease activity
HPO	2	0.00041	0.017	Generalized hyperreflexia
HPO	9	0.00041	0.017	Aplasia/hypoplasia involving the skeleton
HPO	2	0.00041	0.017	Recurrent upper and lower respiratory tract infections
HPO	3	0.00043	0.0175	Convex nasal ridge
HPO	3	0.00043	0.0175	Simplified gyral pattern
InterPro	2	7.92e-05	0.0178	DNA polymerase, Y-family, little finger domain superfamily
InterPro	2	7.92e-05	0.0178	Poly(ADP-ribose) polymerase, regulatory domain superfamily
InterPro	2	7.92e-05	0.0178	XPG conserved site
InterPro	2	7.92e-05	0.0178	DNA glycosylase
InterPro	2	7.92e-05	0.0178	UmuC domain
InterPro	2	7.92e-05	0.0178	DNA polymerase, Y-family, little finger domain
InterPro	2	7.92e-05	0.0178	Poly(ADP-ribose) polymerase, regulatory domain
RCTM	3	0.00047	0.0181	TP53 Regulates Transcription of DNA Repair Genes
Process	14	0.00017	0.0184	Positive regulation of nucleobase-containing compound metabolic process
HPO	5	0.00046	0.0188	Anorectal anomaly
DISEASES	2	0.00011	0.0188	Ataxia telangiectasia
HPO	3	0.00047	0.0189	Chronic diarrhea
RCTM	4	0.00051	0.019	Factors involved in megakaryocyte development and platelet production
HPO	2	0.00047	0.0191	Desquamation of skin soon after birth
HPO	17	0.00048	0.0192	Abnormal nervous system physiology
RCTM	2	0.00055	0.0198	Cytosolic iron-sulfur cluster assembly
Process	2	0.00019	0.0199	Telomere maintenance via semi-conservative replication
RCTM	3	0.00056	0.0199	HDR through Homologous Recombination (HRR)
Keyword	17	0.001	0.0201	Acetylation
Component	12	0.00038	0.0202	Mitochondrion
InterPro	2	0.00011	0.0204	XPG/Rad2 endonuclease
InterPro	2	0.00011	0.0204	XPG-I domain
InterPro	2	0.00011	0.0204	Helix-hairpin-helix motif, class 2
InterPro	2	0.00011	0.0204	SPOC-like, C-terminal domain superfamily
InterPro	2	0.00011	0.0204	5-3 exonuclease, C-terminal domain superfamily
HPO	5	0.00052	0.0206	Abnormal CNS myelination
HPO	6	0.00053	0.0209	Hernia
Component	2	0.00041	0.0214	Transcription factor TFIIH core complex
HPO	10	0.00054	0.0214	Abnormal foot morphology
RCTM	2	0.00062	0.0216	Polymerase switching
HPO	3	0.00056	0.0219	Hypoalbuminemia
HPO	12	0.00056	0.0221	Abnormality of movement
HPO	6	0.00057	0.0221	EEG abnormality
HPO	4	0.00057	0.0222	Abnormality of hair texture
HPO	11	0.00057	0.0223	Abnormality of the lower limb
HPO	4	0.00058	0.0225	Sloping forehead
HPO	3	0.00058	0.0225	Diplopia
HPO	3	0.00058	0.0225	Abnormality of binocular vision
HPO	3	0.00058	0.0225	Abnormal circulating albumin concentration
Component	4	0.00045	0.023	Nuclear periphery
Process	4	0.00022	0.0231	Regulation of DNA biosynthetic process
HPO	12	0.00061	0.0232	Abnormal muscle tone
DISEASES	2	0.00015	0.0233	Omenn syndrome
HPO	10	0.00062	0.0235	Decreased body weight
HPO	2	0.00062	0.0237	Increased mean corpuscular hemoglobin concentration
HPO	2	0.00062	0.0237	Absence of subcutaneous fat
Component	2	0.00047	0.0237	Transcription factor TFIIH holo complex
HPO	2	0.00062	0.0237	Nervous system cancer
InterPro	2	0.00015	0.0241	XPG, N-terminal
Process	8	0.00024	0.0244	Regulation of cell cycle process
Process	2	0.00024	0.0244	Depyrimidination
Process	2	0.00024	0.0244	Protein poly-ADP-ribosylation
Function	2	0.00041	0.0248	U3 snoRNA binding
Keyword	2	0.0013	0.025	Systemic lupus erythematosus
HPO	8	0.00066	0.025	Abnormal retinal morphology
TISSUES	17	0.00011	0.0252	Internal female genital organ
Keyword	5	0.0014	0.0252	Neurodegeneration
HPO	8	0.00068	0.0254	Abnormality of globe location
HPO	9	0.00068	0.0254	Abnormal facial skeleton morphology
TISSUES	16	0.00013	0.0258	Organism form
HPO	4	0.0007	0.0259	Recurrent bacterial infections
Process	4	0.00026	0.0261	B cell differentiation
HPO	2	0.00071	0.0262	Congenital nonbullous ichthyosiform erythroderma
RCTM	2	0.00079	0.0266	Translesion synthesis by REV1
Component	2	0.00055	0.0267	Nuclear telomere cap complex
Process	3	0.00027	0.0272	Regulation of telomerase activity
NetworkNeighborAL	2	0.00011	0.0281	Error-prone translesion synthesis
HPO	4	0.00078	0.0286	Peripheral axonal degeneration
Pfam	2	3.18e-05	0.0288	Ku70/Ku80 C-terminal arm
Pfam	2	3.18e-05	0.0288	ATP dependent DNA ligase domain
Pfam	2	5.29e-05	0.0288	Poly(ADP-ribose) polymerase, regulatory domain
DISEASES	2	0.00019	0.029	Axonal neuropathy
HPO	2	0.00079	0.0291	Diffuse cerebellar atrophy
HPO	5	0.00079	0.0291	Diarrhea
RCTM	2	0.00089	0.0293	Translesion synthesis by POLK
RCTM	2	0.00089	0.0293	Translesion synthesis by POLI
Function	3	0.00049	0.0294	Promoter-specific chromatin binding
HPO	14	0.00081	0.0296	Abnormality of the digestive system
InterPro	2	0.00019	0.0302	Reverse transcriptase/Diguanylate cyclase domain
COMPARTMENTS	2	0.00055	0.0307	Nuclear telomere cap complex
HPO	3	0.00086	0.031	Retinopathy
HPO	4	0.00086	0.031	Neoplasm of the genitourinary tract
COMPARTMENTS	3	0.00058	0.0311	Replication fork
Component	11	0.00069	0.0313	Catalytic complex
Process	12	0.00032	0.0314	Regulation of cell death
Component	2	0.00071	0.0314	Replisome
Function	11	0.00053	0.0314	ATP binding
Component	8	0.00072	0.0315	Transferase complex
Process	6	0.00032	0.0316	Leukocyte differentiation
RCTM	2	0.00098	0.0316	TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
HPO	2	0.00089	0.0319	Concave nail
TISSUES	5	0.00018	0.0319	Chronic lymphocytic leukemia cell
TISSUES	11	0.00017	0.0319	Skeletal system
TISSUES	5	0.00019	0.0319	Fibroblast
Function	2	0.00055	0.0321	3-5-exodeoxyribonuclease activity
TISSUES	15	0.00021	0.0321	Embryonic structure
HPO	7	0.0009	0.0324	Abnormal optic disc morphology
HPO	9	0.0009	0.0324	Upper motor neuron dysfunction
Process	16	0.00033	0.0326	Negative regulation of macromolecule metabolic process
COMPARTMENTS	3	0.00063	0.0326	Nuclear matrix
HPO	3	0.00092	0.0329	Increased bone mineral density
HPO	9	0.00094	0.0333	Abnormal anterior eye segment morphology
Process	2	0.00035	0.0334	Error-prone translesion synthesis
RCTM	2	0.0011	0.0344	Translesion Synthesis by POLH
HPO	2	0.00098	0.0348	Astrocytoma
HPO	3	0.00099	0.0349	Enamel hypoplasia
HPO	3	0.00099	0.0349	Intention tremor
HPO	6	0.00099	0.035	Tremor
HPO	5	0.001	0.0355	Abnormality of the thyroid gland
NetworkNeighborAL	2	0.00015	0.0355	Mixed, incl. Protein of unknown function DUF3504, and Telomeric repeat-containing RNA binding
Pfam	2	7.92e-05	0.0358	impB/mucB/samB family C-terminal domain
Pfam	2	7.92e-05	0.0358	impB/mucB/samB family
HPO	4	0.0011	0.0371	Abnormal adipose tissue morphology
TISSUES	27	0.00026	0.0376	Reproductive system
TISSUES	5	0.00028	0.0376	Erythroleukemia cell
HPO	2	0.0011	0.0376	Cerebral dysmyelination
HPO	2	0.0011	0.0376	Recurrent aphthous stomatitis
HPO	5	0.0011	0.0376	Abnormal breast morphology
HPO	4	0.0011	0.0381	Gait ataxia
HPO	3	0.0011	0.0386	Oculomotor apraxia
TISSUES	26	0.0003	0.0388	Female reproductive system
Function	2	0.00071	0.04	Endodeoxyribonuclease activity, producing 5-phosphomonoesters
HPO	2	0.0012	0.0406	Progeroid facial appearance
RCTM	10	0.0013	0.0408	Post-translational protein modification
HPO	12	0.0012	0.0414	Abnormality of the ear
HPO	4	0.0012	0.0414	Apraxia
HPO	4	0.0012	0.0419	Ectopic calcification
HPO	3	0.0012	0.042	Kinetic tremor
Process	5	0.00045	0.0429	Cellular response to chemical stress
HPO	8	0.0013	0.0431	Abnormality of the forehead
RCTM	6	0.0014	0.0431	Cell Cycle, Mitotic
NetworkNeighborAL	2	0.00019	0.0433	Peptidyl-serine ADP-ribosylation, and poly(ADP-ribose) glycohydrolase activity
COMPARTMENTS	2	0.00089	0.0443	BAX complex
HPO	3	0.0013	0.0445	Lymphoma
InterPro	3	0.00029	0.0445	SMAD/FHA domain superfamily
HPO	8	0.0013	0.0449	Involuntary movements
Process	2	0.00047	0.0451	Protein auto-ADP-ribosylation
Process	2	0.00047	0.0451	Regulation of helicase activity
Process	2	0.00047	0.0451	Cellular response to X-ray
Process	3	0.00049	0.0453	T cell differentiation in thymus
HPO	7	0.0014	0.0459	Recurrent infections
Process	5	0.0005	0.0464	Lymphocyte differentiation
Process	3	0.00051	0.0466	Regulation of telomere maintenance via telomere lengthening
Process	9	0.00051	0.0466	Negative regulation of cell death
HPO	2	0.0014	0.0472	Ridged nail
HPO	2	0.0014	0.0472	Aphthous ulcer
HPO	4	0.0014	0.0473	Abnormal circulating lipid concentration
HPO	6	0.0014	0.0478	Abnormal peripheral nervous system morphology
Process	11	0.00053	0.0479	Regulation of programmed cell death
Process	3	0.00053	0.0479	Activation of innate immune response
Keyword	11	0.0027	0.0485	Transferase
Process	2	0.00055	0.0487	UV-damage excision repair
